Abstract:Several Conus-derived venom peptides are promising lead compounds for the management of neuropathic pain, with α-conotoxins being of particular interest. Modification of the interlocked disulfide framework of α-conotoxin Vc1.1 has been achieved using on-resin alkyne metathesis. Although introduction of a metabolically stable alkyne motif significantly disrupts backbone topography, the structural modification generates a potent and selective GABAB receptor agonist that inhibits Cav2.2 channels and exhibits dose-dependent reversal of mechanical allodynia in a behavioral rat model of neuropathic pain. The findings herein support the hypothesis that analgesia can be achieved via activation of GABABRs expressed in dorsal root ganglion (DRG) sensory neurons.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02151?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02151</a>.Figures illustrating the (i) RP-HPLC and ESI-MS profiles of synthesized dicarba peptides 3 and 4; (ii) 1H NMR spectra of peptides 1 and 3; (iii) Vc1.1 1 activity at human α3β2, hα3β4, hα6/α3β4, hα9α10, and hα7 nAChR subtypes; (iv) concentration–response relationships for [2,8]-alkyne Vc1.1 3 and Vc1.1 1 inhibition of Cav2.2-mediated Ba2+ currents in HEK293T cells transfected with human Cav2.2 channels and human GABAB R1 and R2 subunits; and (v) [2,8]-alkyne Vc1.1 3 inhibition of high-voltage-activated calcium channel currents in an adult mouse dorsal root ganglion sensory neuron. Additional tables with (i) chemical shift assignments of the dicarba analogue 3 and experimental constraints along with structural statistics; (ii) ipsilateral PWT changes over time in Chung model rats following administration of vehicle, alkyne Vc1.1 3, and gabapentin; and (iii) molecular formula strings for peptides 3 and 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02151/suppl_file/jm0c02151_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an effective method for treating neuropathic pain. Specifically, by introducing an alkynyl - bridged structure into α - conotoxin Vc1.1, the researchers created a new type of GABA B receptor agonist. This compound can selectively activate the GABA B receptor and inhibit the Ca_v2.2 channel, thus showing a dose - dependent reversal effect of mechanical allodynia in animal models of neuropathic pain. This finding supports the hypothesis that analgesia can be achieved by activating the GABA B receptor in dorsal root ganglion (DRG) sensory neurons. The main objective of the paper is to evaluate the effectiveness and mechanism of this new Vc1.1 analogue as a potential drug for treating neuropathic pain.

Alkyne-Bridged α-Conotoxin Vc1.1 Potently Reverses Mechanical Allodynia in Neuropathic Pain Models

Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at the alpha9alpha10 nicotinic acetylcholine receptor

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Dual Antagonism of α9α10 nAChR and GABA B Receptor-Coupled Ca V 2.2 Channels by an Analgesic αO-Conotoxin Analogue

Makatoxin-3, a Thermostable Nav1.7 Agonist from Buthus Martensii Karsch (bmk) Scorpion Elicits Non-Narcotic Analgesia in Inflammatory Pain Models.

Development of an Intravenously Stable Disulfide-Rich Peptide for the Treatment of Chemotherapy-Induced Neuropathic Pain

Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine Receptors

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Design, synthesis, and mechanism of action of novel μ-conotoxin KIIIA analogues for inhibition of the voltage-gated sodium channel Nav1.7

α9-Nicotinic Acetylcholine Receptors Contribute to the Maintenance of Chronic Mechanical Hyperalgesia, but Not Thermal or Mechanical Allodynia

An anchor-tether 'hindered' HCN1 inhibitor is antihyperalgesic in a rat spared nerve injury neuropathic pain model

Phα1β toxin prevents capsaicin-induced nociceptive behavior and mechanical hypersensitivity without acting on TRPV1 channels

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain

Novel Scorpion Toxin ω-Buthitoxin-Hf1a Selectively Inhibits Calcium Influx via CaV3.3 and CaV3.2 and Alleviates Allodynia in a Mouse Model of Acute Postsurgical Pain

N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor

A novel ω-conotoxin Bu8 inhibiting N-type voltage-gated calcium channels displays potent analgesic activity

The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain

Analgesic effects of the CTK 01512-2 toxin in different models of orofacial pain in rats

The conotoxin Contulakin-G reverses hypersensitivity observed in rodent models of cancer-induced bone pain without inducing tolerance or motor disturbance

Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor